Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoreserpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 1.00 |
| ▸ | HBB | P68871 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reserpine SCHEMBL20402680 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL15385127 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL1172973 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL4562878 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL12732449 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL8262666 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL14379427 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL5372164 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL22002247 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL29375859 | 1.00 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS | 2020-03-10 | — | — | US | claimed |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | UNM RAINFOREST INNOVATIONS | 2019-09-05 | — | — | US | claimed |
| WO-2018148113-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | STC.UNM (US) | 2018-08-16 | — | — | WO | claimed |
| US-20150148256-A1 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-05-28 | — | — | US | claimed |
| US-20130345249-A1 | Formulations for the prevention and treatment of Wolbachia-related disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-26 | — | — | US | claimed |
| WO-2012097258-A2 | FORMULATIONS FOR THE PREVENTION AND TREATMENT OF WOLBACHIA-RELATED DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-19 | — | — | WO | claimed |
| US-20110250129-A1 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-13 | — | — | US | claimed |
| EP-2356248-A2 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 | The Johns Hopkins University (US) | 2011-08-17 | — | — | EP | claimed |
| WO-2010056858-A2 | BIOLUMINESCENCE IMAGING-BASED SCREENING ASSAY AND INHIBITORS OF ABCG2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2006017185-A1 | DRUGS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | ODYSSEY THERA, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060009506-A1 | Drugs for the treatment of neoplastic disorders | ODYSSEY THERA, INC. (US) | 2006-01-12 | — | — | US | claimed |
| US-11331284-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200237687-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | UNM RAINFOREST INNOVATIONS | 2020-07-30 | — | — | US | disclosed |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | UNM RAINFOREST INNOVATIONS | 2020-03-10 | — | — | US | disclosed |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | UNM RAINFOREST INNOVATIONS | 2019-09-05 | — | — | US | disclosed |
| EP-0961612-A1 | PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | Vivorx Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5916596-A | WATER INSOLUBLE DRUGS AND DRUG DELIVERY | VIVORX PHARMACEUTICALS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1999000113-A9 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS INC (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999000113-A1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998014174-A1 | PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331284-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | BECN1, RABGGTB, ATG7 | SLC18A2 2779/4885MEN1 591/4885KMT2A 3238/4885 |
| US-20190269806-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | BECN1, RABGGTB, TFEB | SLC18A2 3735/4885MEN1 800/4885KMT2A 3401/4885 |
| US-10583099-B2 | Isotope enhanced ambroxol for long lasting autophagy induction | BECN1, TFEB, ATG7 | SLC18A2 2393/4885MEN1 849/4885KMT2A 3603/4885 |
| US-20200237687-A1 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | BECN1, RABGGTB, TFEB | SLC18A2 3145/4885MEN1 744/4885KMT2A 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.